Table 1.
Subject Characteristics at Main Baseline (Day −29)
| Treatment Group | Alirocumab 150 mg Q4W+Placebo (n=24) | Alirocumab 150 mg Q4W+Ezetimibe (n=24) | Alirocumab 150 mg Q4W+Fenofibrate (n=24) |
|---|---|---|---|
| Age, y | 48.5 (12.8) | 49.5 (10.7) | 54.6 (7.6) |
| Male, n (%) | 11 (45.8) | 11 (45.8) | 10 (41.7) |
| Race, n (%) | |||
| Caucasian/white | 23 (95.8) | 21 (87.5) | 24 (100) |
| Black | 1 (4.2) | 3 (12.5) | 0 |
| Body mass index, kg/m2 | 23.9 (2.0) | 25.5 (2.7) | 24.7 (2.5) |
| Calculated LDL‐C, mg/dL | 183.3 (38.7) | 181.7 (37.1) | 180.6 (31.3) |
| Total cholesterol, mg/dL | 264.5 (43.7) | 260.6 (40.6) | 263.7 (40.6) |
| Apolipoprotein B, g/L | 1.28 (0.21) | 1.28 (0.22) | 1.28 (0.17) |
| Non–HDL‐C, mg/dL | 198.4 (40.6) | 200.3 (39.8) | 199.5 (31.7) |
| HDL‐C, mg/dL | 65.7 (12.4) | 60.3 (13.1) | 64.2 (15.5) |
| Apolipoprotein A1, g/L | 1.58 (0.16) | 1.55 (0.21) | 1.57 (0.20) |
| Triglycerides (mg/dL), median (range) | 78.8 (44.3–177.1) | 95.7 (35.4–168.3) | 94.8 (53.1–194.9) |
| Lipoprotein(a) (g/L), median (range) | 0.27 (0.0–1.6) | 0.33 (0.0–1.6) | 0.17 (0.0–1.5) |
| Free PCSK9, ng/mL | 146.5 (54.3) | 150.7 (48.5) | 152.1 (54.1) |
Values are mean (SD) unless otherwise stated. HDL‐C indicates high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin/kexin type 9; Q4W, every 4 weeks.